Item 8.01. Other Events.



On March 5, 2021, BeiGene, Ltd. (the "Company") announced that a supplemental
Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab was
accepted by the Center for Drug Evaluation (CDE) of the China National Medical
Products Administration (NMPA) for treatment in the second- or third-line
setting of patients with locally advanced or metastatic non-small cell lung
cancer (NSCLC) who have progressed on prior platinum-based chemotherapy. The
full text of this press release is filed as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.           Description

       99.1              Press Release titled "BeiGene Announces Acceptance

of a Supplemental Biologics


                         License Application in China for Tislelizumab in Second- or Third-line
                         Non-Small Cell Lung Cancer" issued on March 5, 2021.
       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.


--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.           Description

       99.1                Press Release titled "BeiGene Announces

Acceptance of a Supplemental Biologics


                         License Application in China for Tislelizumab in

Second- or Third-line Non-Small


                         Cell Lung Cancer"     issued on March 5, 2021.

       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses